174 related articles for article (PubMed ID: 38382930)
1. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN; Jiang X; Song P; Tang W
Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
4. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.
Whitham Z; Hsiehchen D
Surg Oncol Clin N Am; 2024 Jan; 33(1):87-97. PubMed ID: 37945147
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
6. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
[TBL] [Abstract][Full Text] [Related]
8. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
11. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
12. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
[TBL] [Abstract][Full Text] [Related]
13. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.
Pourhamzeh M; Asadian S; Mirzaei H; Minaei A; Shahriari E; Shpichka A; Es HA; Timashev P; Hassan M; Vosough M
Mol Cell Biochem; 2023 Jan; 478(1):23-37. PubMed ID: 35708866
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis.
Han YH; Bo JQ; Liu LX
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7134-7147. PubMed ID: 37606124
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
Samuel M; Chow PK; Chan Shih-Yen E; Machin D; Soo KC
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD001199. PubMed ID: 19160192
[TBL] [Abstract][Full Text] [Related]
16. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Tovoli F; De Lorenzo S; Trevisani F
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33023131
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.
Abdelrahim M; Esmail A; Umoru G; Westhart K; Abudayyeh A; Saharia A; Ghobrial RM
Curr Oncol; 2022 Jun; 29(6):4267-4273. PubMed ID: 35735450
[TBL] [Abstract][Full Text] [Related]
19. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
20. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
